Karina Juhl

Karina Juhl

Auto-generated profile, based on publicly available information

Karina Juhl

Copenhagen University Hospital, University of Copenhagen, Rigshospitalet & Department of Biomedical Sciences, Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ACAnders Christensen
Anders Christensen
KKKatalin Kiss
Katalin Kiss
GLGiedrius Lelkaitis
Giedrius Lelkaitis
KJKarina Juhl
Karina Juhl
MPMorten Persson
Morten Persson
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
Tumor-specific biomarkers are a prerequisite for the development of targeted imaging and therapy in oral squamous cell carcinoma (OSCC). urokinase-type Plasminogen Activator Receptor (uPAR), Tissue Factor (TF) and Epidermal Growth Factor Receptor (EGFR) are three biomarkers that exhibit enhanced expression in many types of cancers, and have been investigated as potential biomarkers for targeted strategies and prognostication. The aim of the study was to investigate the expression patterns of uPAR, TF and EGFR and their potential prognostic value in OSCC. Immunohistochemical expression of uPAR, TF and EGFR in tumor resection specimens from 191 patients with primary OSCC was analyzed. Overall (OS) and disease-free survival (DFS) was calculated. Associations between biomarker expression, clinicopathological factors and patient survival was analyzed using the Cox proportional hazards model for univariate and multivariate analysis, log rank and Kaplan-Meier statistics. uPAR and TF exhibited a highly tumor-specific expression pattern while EGFR also showed expression in normal tissues outside the tumor compartment. The overall positive expression rate of uPAR, TF and EGFR was 95%, 58% and 98%, respectively. High uPAR expression across the entire cohort was negatively associated with OS (p = 0.031, HR = 1.595 (95%CI 1.044–2.439)) in univariate analysis. The 5-year OS for high and low uPAR expression was 39% and 56%, respectively. The expression of TF and EGFR was not associated with survival outcome. This study may suggest that uPAR and TF could potentially be attractive targets for molecular imaging and therapy in OSCC due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. uPAR seems to be a prognostic biomarker in oral cancer.

Verified
Journal Article
Open access
PDF file
MLMads Lawaetz
Mads Lawaetz
ACAnders Christensen
Anders Christensen
KJKarina Juhl
Karina Juhl
KKKirstine Karnov
Kirstine Karnov
GLGiedrius Lelkaitis
Giedrius Lelkaitis
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
No clinically approved tumor-specific imaging agents for head and neck cancer are currently available. The identification of biomarkers with a high and homogenous expression in tumor tissue and minimal expression in normal tissue is essential for the development of new molecular imaging targets in head and neck cancer. We investigated the expression of nine imaging targets in both primary tumor and matched metastatic tissue of 41 patients with oral squamous cell carcinoma (OSCC) to assess their potential as targets for molecular imaging. The intensity, proportion, and homogeneity in the tumor and the reaction in neighboring non-cancerous tissue was scored. The intensity and proportion were multiplied to obtain a total immunohistochemical (IHC) score ranging from 0–12. The mean intensity in the tumor tissue and normal epithelium were compared. The expression rate was high for the urokinase-type plasminogen activator receptor (uPAR) (97%), integrin αvβ6 (97%), and tissue factor (86%) with a median total immunostaining score (interquartile range) for primary tumors of 6 (6–9), 12 (12–12), and 6 (2.5–7.5), respectively. For the uPAR and tissue factor, the mean staining intensity score was significantly higher in tumors compared to normal epithelium. The uPAR, integrin αvβ6, and tissue factor are promising imaging targets for OSCC primary tumors, lymph node metastases, and recurrences.

1 November 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
ACAnders Christensen
Anders Christensen
KJKarina Juhl
Karina Juhl
KKKatalin Kiss
Katalin Kiss
GLGiedrius Lelkaitis
Giedrius Lelkaitis
BCBirgitte Wittenborg Charabi
Birgitte Wittenborg Charabi
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
Lymph node yield (LNY) in neck dissection has been identified as a prognostic factor in oral cavity cancer. The purpose of this study was to investigate the impact of additional use of optical imaging on LNY in therapeutic ND in oral cancer. Consecutive patients with oral squamous cell carcinoma with clinical neck metastasis planned for primary tumor resection were randomized to conventional neck dissection or near-infrared fluorescence (NIRF)-guided neck dissection, respectively. In the intervention group, patients were injected with ICG-Nanocoll prior to surgery. Intraoperatively, an optical hand-held camera system was used for lymph node identification. Also, NIRF imaging of the neck specimen was performed, and optical signals were pinned with needle markings to guide the pathological examination. The endpoint of the study was LNY per neck side in levels Ib-III. 31 patients were included with 18 neck sides in the control group and 18 neck sides in the intervention group for evaluation. During NIRF-guided ND, individual lymph nodes could be identified by a bright fluorescent signal and individual tumor-related drainage patterns could be observed in the neck. The LNY in the intervention group was significantly higher compared to the control group (p = 0.032) with a mean of 24 LN (range: 12-33 LN in levels Ib-III compared to 18 LN (range: 10-36 LN) in the control group, respectively. NIRF-guided ND significantly improved the nodal yield compared to the control group. Intraoperative real-time optical imaging enabled direct visualization of tumor-related drainage patterns within the neck lymphatics.

3 June 2025 in Neurosurgery
Verified
Journal Article
Open access
JSJane Skjøth-Rasmussen
Jane Skjøth-Rasmussen
AAAleena Azam
Aleena Azam
KJKarina Juhl
Karina Juhl
SGSara Ginsborg
Sara Ginsborg
MSMartin Kryspin Sørensen
Martin Kryspin Sørensen
Andreas KjaerAndreas Kjaer
Andreas Kjaer
BACKGROUND AND OBJECTIVES: Glioblastoma is an aggressive form of brain cancer for which surgery is the keystone in treatment before oncological treatment. Improving surgical resection without jeopardizing the outcome is eminent, and a fluorescent drug to aid surgical outcome is warranted. To evaluate the safety and the efficacy of a novel urokinase-type Plasminogen Activator Receptor-targeting near-infrared optical imaging agent, ICG-Glu-Glu-AE105 (FG001), in patients with malignant glioma (glioblastoma). METHODS: First-in-human phase I dose escalation and time elaboration study in 35 patients undergoing surgery for glioblastoma. The tumor-to-background ratio (TBR) was measured on near-infrared images as an objective measure of image contrast. Biopsies were taken during surgery from areas with and without fluorescence (FG001) and compared with pathology as reference. Efficacy was evaluated as sensitivity and specificity of FG001 to detect tumor tissue. The study was conducted with close safety monitoring. RESULTS: Administration of FG001 at a dose of 36 mg, 12 to 17 hours before surgery, resulted in optimal image contrast between tumor and normal brain tissue, with a mean TBR of 3.6. A high sensitivity (79%) and specificity (100%) for the detection of tumor tissue was found. Safety monitoring during the study identified only a few related adverse events, all of which were of mild grade. CONCLUSION: FG001 was found to be safe and well tolerated in the patients included in the study. The optimal dose of FG001 was selected on the basis of videos taken during the surgery and the measured TBR values. A dose of 36 mg administered 16 hours (mean) before the surgery showed the best contrast (TBR values) and optimal visualization of the tumor delineation. Histology demonstrated good sensitivity of FG001.

11 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JVJosephine Volovetz
Josephine Volovetz
LBLine V. Buchwald
Line V. Buchwald
KSKarina Straede
Karina Straede
Andreas KjaerAndreas Kjaer
Andreas Kjaer
MGMatthew Grabowski
Matthew Grabowski
JLJustin Lathia
Justin Lathia
Glioblastoma (GBM) remains a challenging tumor in terms of clinical management, with limited progress made since the standard of care was established in 2005. Maximal safe surgical resection, a cornerstone of the standard-of-care regimen, is a major determinant in patient outcome. However, this key clinical parameter is generally not accounted for in preclinical models, which are often used to provide a rationale for early-phase clinical trials. In this perspective, we cover the current types and status of preclinical GBM resection models and the insights they provide into the GBM disease process. In addition, we discuss how surgical resection alters the immune response, which can affect response to therapies, especially in the context of newly developing and contemporary immunotherapies. Given the complexity of GBM and the use of tumor resection in clinical management, we highlight the necessity and opportunity to integrate surgical resection into preclinical models to help inform and test the next generation of treatments.

25 October 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MLMads Lawaetz
Mads Lawaetz
ACAnders Christensen
Anders Christensen
KJKarina Juhl
Karina Juhl
GLGiedrius Lelkaitis
Giedrius Lelkaitis
KKKirstine Karnov
Kirstine Karnov
Andreas KjaerAndreas Kjaer
Andreas Kjaer
The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). 68Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen activator receptor (uPAR), a receptor expressed on the surfaces of tumor cells. The aim of this study was to investigate the diagnostic value of uPAR-PET/CT (computerized tomography) in detecting regional metastatic disease in patients with OSCC and OPSCC compared to the current imaging work-up. In this phase II trial, patients with OSCC and OPSCC referred for surgical treatment were prospectively enrolled. Before surgery, 68Ga-NOTA-AE105 uPAR-PET/CT was conducted, and SUVmax values were obtained from the primary tumor and the suspected lymph nodes. Histology results from lymph nodes were used as the standard of truth of metastatic disease. The diagnostic values of 68Ga-uPAR-PET/CT were compared to conventional routine preoperative imaging results (CT and/or MRI). The uPAR expression in resected primary tumors and metastases was determined by immunohistochemistry and quantified digitally (H-score). A total of 61 patients underwent uPAR-PET/CT. Of the 25 patients with histologically verified lymph node metastases, uPAR-PET/CT correctly identified regional metastatic disease in 14 patients, with a median lymph node metastasis size of 14 mm (range 3–27 mm). A significant correlation was found between SUVmax and the product of the H-score and tumor depth (r = 0.67; p = 0.003). The sensitivity and specificity of uPAR-PET/CT in detecting regional metastatic disease were 56% and 100%, respectively. When added to CT/MRI, uPAR-PET was able to upstage 2/11 (18%) of patients with occult metastases and increase the sensitivity to 64%. The sensitivity and specificity of 68Ga-NOTA-AE105 uPAR-PET/CT were equivalent to those of CT/MRI. The significant correlation between SUVmax and uPAR expression verified the target specificity of 68Ga-NOTA-AE105. Despite the target specificity, the sensitivity of imaging is too low for nodal staging and it cannot replace neck dissection.